GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SMO Clinplus Co Ltd (SZSE:301257) » Definitions » Gross Profit

SMO Clinplus Co (SZSE:301257) Gross Profit : ¥239.2 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is SMO Clinplus Co Gross Profit?

SMO Clinplus Co's gross profit for the three months ended in Mar. 2024 was ¥46.7 Mil. SMO Clinplus Co's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ¥239.2 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. SMO Clinplus Co's gross profit for the three months ended in Mar. 2024 was ¥46.7 Mil. SMO Clinplus Co's Revenue for the three months ended in Mar. 2024 was ¥184.5 Mil. Therefore, SMO Clinplus Co's Gross Margin % for the quarter that ended in Mar. 2024 was 25.33%.

SMO Clinplus Co had a gross margin of 25.33% for the quarter that ended in Mar. 2024 => Competition eroding margins

During the past 7 years, the highest Gross Margin % of SMO Clinplus Co was 34.28%. The lowest was 26.08%. And the median was 30.41%.

Warning Sign:

SMO Clinplus Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -2.8%.


SMO Clinplus Co Gross Profit Historical Data

The historical data trend for SMO Clinplus Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMO Clinplus Co Gross Profit Chart

SMO Clinplus Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 99.80 97.65 131.19 159.98 231.10

SMO Clinplus Co Quarterly Data
Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.63 60.30 65.80 66.36 46.74

Competitive Comparison of SMO Clinplus Co's Gross Profit

For the Diagnostics & Research subindustry, SMO Clinplus Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SMO Clinplus Co's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where SMO Clinplus Co's Gross Profit falls into.



SMO Clinplus Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

SMO Clinplus Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=760.043 - 528.941
=231.1

SMO Clinplus Co's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=184.533 - 137.796
=46.7

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥239.2 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

SMO Clinplus Co's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=46.7 / 184.533
=25.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


SMO Clinplus Co  (SZSE:301257) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

SMO Clinplus Co had a gross margin of 25.33% for the quarter that ended in Mar. 2024 => Competition eroding margins


SMO Clinplus Co Gross Profit Related Terms

Thank you for viewing the detailed overview of SMO Clinplus Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


SMO Clinplus Co (SZSE:301257) Business Description

Traded in Other Exchanges
N/A
Address
No. 105 Sinan Road, Room 108, Building 1, Huangpu District, Shanghai, CHN, 200001
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
Executives
Lai Chun Bao Director
Ma Lin Director

SMO Clinplus Co (SZSE:301257) Headlines

No Headlines